ARWR: financial statements from SEC — TradeAlmanac

ARWR

Arrowhead Pharmaceuticals, Inc.: financial statements

Company reports as filed with the U.S. Securities and Exchange Commission.

AnnualQuarterly

Income statement

Metric	Mar 31, 2026	Dec 31, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Jun 30, 2024
Revenue	74m	264m	28m	543m	3m	0
Research and development	173m	177m	—	133m	137m	—
Selling, general and administrative	42m	46m	31m	28m	27m	24m
Operating expenses	215m	223m	193m	162m	164m	176m
Operating income	−141m	41m	−166m	381m	−161m	−176m
Pre-tax income	−138m	28m	−179m	370m	−175m	−174m
Income tax	7,000	29,000	−437,000	2m	103,000	0
Net income	−133m	31m	−175m	368m	−173m	−171m
Earnings per share	−0.93	0.22	−1.26	2.78	−1.39	−1.38
Earnings per share, diluted	−0.93	0.22	−1.26	2.75	−1.39	−1.38
Weighted average shares	142m	137m	139m	133m	125m	124m
Weighted average shares, diluted	142m	141m	139m	134m	125m	124m

Balance sheet

Metric	Mar 31, 2026	Dec 31, 2025	Sep 30, 2025	Jun 30, 2025	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024
Cash and equivalents	189m	202m	227m	130m	186m	54m	103m	69m
Short-term investments	1.60bn	715m

Cash flow

Metric	Dec 31, 2025	Dec 31, 2024
Operating cash flow	13m	−146m
Depreciation and amortisation	6m	5m
Share-based compensation	19m	15m
Capital expenditure	2m	8m
Investing cash flow	−24m	77m
Financing cash flow	−15m

Amounts in USD unless stated otherwise. Sources: Nasdaq Trader, Yahoo Finance, U.S. Securities and Exchange Commission (EDGAR)